Detection of Spectrin and Spectrin Proteolytic Cleavage Products in Assessing Nerve Cell Damage
ALACHUA, Fla. (PRWEB) December 12, 2008
Gary Ascani, Chief Executive Officer of Banyan Biomarkers, Inc., commented, "We are very pleased with the addition of this patent to Banyan's intellectual property portfolio of TBI biomarkers. With nearly 2 million people experiencing TBI annually in the United States and no available point-of-care diagnostic test, Banyan is paving the way in establishing the leadership position in the discovery, validation and development of products for the detection of traumatic brain injury."
Banyan Biomarkers also has exclusive licenses from the University of Florida for U.S. Patent no. 7,291,710 "Detection of Spectrin and Spectrin Proteolytic Cleavage Products in Assessing Nerve Cell Damage" and U.S. Patent No. 7,396,654 "Neural Proteins as Biomarkers for Traumatic Brain Injury."
To learn more about Banyan Biomarkers, Inc., visit http://www.banyanbio.com/.